| | 253128-41-5 Basic information More.. |
| Product Name: | Eribulin | | Synonyms: | Eribulin;B 1939;E 7389;ER 086526;US-DMF No. : 035118;DMF No. : 035118;Eribulin USP/EP/BP;(1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-Amino-2-
hydroxypropyl]-21-methoxy-14-methyl-8,15-bis(methylene)-2,19,30,34,37,39,40,41-octaoxanonacyclo
[24.9.2.1 3,32 .1 3,33 .1 6,9 .1 12,16 .0 18,22 .0 29,36 .0 31,35 ]hentetracontan-24-one | | CAS: | 253128-41-5 | | MF: | C40H59NO11 | | MW: | 729.9 | | EINECS: | 803-583-7 | | Mol File: | 253128-41-5.mol |  |
Use
The U.S. FDA approved eribulin mesylate (also referred to as E7389) in
November 2010 for the treatment of metastatic breast cancer (MBC) for
patients who previously received at least two chemotherapeutic regimens
for late-stage disease. Eribulin is a synthetic analog of the marine natural product halichondrin B, which is isolated from the sea sponge Halichondria okadai. Eribulin retains most of
the structural elements that constitute the right hand side of halichondrin
B; structure–activity relationship (SAR) studies suggested that the antitumor
activity of halichondrin B resides in that part of the molecule .
Eribulin is a microtubule inhibitor that binds close to the vinca-binding
site of tubulin. Unlike most tubulin inhibitors like taxanes, epothilones,
and vinca alkaloids that inhibit microtubule dynamic instability by changing
tubulin addition and loss parameters, eribulin’s effects on dynamic
instability are novel in that eribulin inhibits the growth phase of microtubules
without affecting the shortening phase by binding to microtubule
plus ends.
- Eribulin
-
- US $0.00-0.00 / kg
- 2022-09-30
- CAS:253128-41-5
- Min. Order: 1kg
- Purity: 98%
- Supply Ability: 1Ton
- Eribulin
-
- US $0.00-0.00 / G
- 2022-05-11
- CAS:253128-41-5
- Min. Order: 1G
- Purity: 99%HPLC
- Supply Ability: 100KG
- Eribulin
-
- US $12.00 / g
- 2021-11-27
- CAS:253128-41-5
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 5ton/Month
|
|
253128-41-5
Recommend Suppliers |
|